Jonathan Tegge - InMed Pharmaceuticals Interim Officer
| INM Stock | USD 4.29 0.01 0.23% |
Executive
Jonathan Tegge is Interim Officer of InMed Pharmaceuticals
| Age | 34 |
| Address | 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 |
| Phone | 604 669 7207 |
| Web | https://www.inmedpharma.com |
InMed Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.3922) % which means that on every $100 spent on assets, it lost $0.3922. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7209) %, meaning that it generated no profit with money invested by stockholders. InMed Pharmaceuticals' management efficiency ratios could be used to measure how well InMed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, InMed Pharmaceuticals' Return On Capital Employed is very stable compared to the past year. As of the 29th of November 2024, Return On Equity is likely to grow to 6.45, while Return On Tangible Assets are likely to drop (4.61). At this time, InMed Pharmaceuticals' Tangible Asset Value is very stable compared to the past year. As of the 29th of November 2024, Intangibles To Total Assets is likely to grow to 0.40, while Net Tangible Assets are likely to drop about 9.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD FACC | ZyVersa Therapeutics | 74 | |
| MPH MD | Tonix Pharmaceuticals Holding | N/A | |
| Alexander Epshinsky | Allarity Therapeutics | 41 | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| John Niles | GeoVax Labs | N/A | |
| David Marks | Immix Biopharma | N/A | |
| John Sharkey | GeoVax Labs | 68 | |
| Ben JD | Immix Biopharma | N/A | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Steve Ellul | Biodexa Pharmaceticals | N/A | |
| Thomas OBrien | GeoVax Labs | N/A | |
| Sina Bavari | Tonix Pharmaceuticals Holding | N/A | |
| MD FFPM | Immix Biopharma | 64 | |
| James Wang | Virax Biolabs Group | N/A | |
| Darryl Rideout | Tonix Pharmaceuticals Holding | N/A | |
| Sai Iyer | LMF Acquisition Opportunities | N/A | |
| Thomas Englese | Tonix Pharmaceuticals Holding | 50 | |
| Jose MD | Allarity Therapeutics | 67 | |
| Gregory MD | Tonix Pharmaceuticals Holding | 58 | |
Management Performance
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.39 |
InMed Pharmaceuticals Leadership Team
Elected by the shareholders, the InMed Pharmaceuticals' board of directors comprises two types of representatives: InMed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InMed. The board's role is to monitor InMed Pharmaceuticals' management team and ensure that shareholders' interests are well served. InMed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InMed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sazzad MSc, CoFounder | ||
| MIB Chem, CEO President | ||
| Ado Muhammad, Consultant Affairs | ||
| Colin Clancy, Director Relations | ||
| Eric Hsu, Senior Development | ||
| Netta Jagpal, CFO Secretary | ||
| Jerry Griffin, Vice Marketing | ||
| Jonathan Tegge, Interim Officer | ||
| Michael PEng, Chief Officer | ||
| Shane Johnson, Senior BayMedica | ||
| CGA CPA, Controller Accounting | ||
| Alexandra MSc, Senior Affairs |
InMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InMed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.67) % | ||||
| Operating Margin | (1.57) % | ||||
| Current Valuation | (1.44 M) | ||||
| Shares Outstanding | 718.08 K | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 25.85 K | ||||
| Price To Book | 0.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.